[Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Zhonghua Gan Zang Bing Za Zhi
; 18(2): 109-12, 2010 Feb.
Article
em Zh
| MEDLINE
| ID: mdl-20196949
ABSTRACT
OBJECTIVE:
To analyze antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis.METHODS:
104 patients of hepatitis B virus-related cirrhosis with no previous history of antiviral therapy were treated with entecavir 0.5 mg once daily. 37 patients were taken hepatic histologic examination before and after the treatment.RESULTS:
Mean reductions of serum HBV DNA was 5.1 log10 96 weeks after the treatment, HBV DNA became undetectable in 98.1% patients, and ALT became normal in 80.7% patients; HBeAg seroconversion occurred in 13.9% of the 72 HBeAg positive patients; 61.5% of these patients were infected with genotype C HBV, and 26.9% were infected with genotype B HBV. The genotype of HBV was not associated with the therapeutical effect. Child-pugh score was associated with the progression of the disease the proportion of patients with disease progression was highest in Child-Pugh C grade patients and lowest in Child-Pugh A grade patients. The level of the HBV DNA load was positively correlated with Knodell HAI score at the baseline and 96 weeks after the treatment.CONCLUSION:
Entecavir treatment results in suppression of HBV replication and delayed progression of fibrosis in patients with hepatitis B virus-related cirrhosis.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
DNA Viral
/
Hepatite B Crônica
/
Guanina
/
Cirrose Hepática
Tipo de estudo:
Etiology_studies
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Zh
Ano de publicação:
2010
Tipo de documento:
Article